New blood test may someday help guide the best treatment for aggressive prostate cancer

Tumors that spread, or metastasize, in the body shed cells into blood that doctors can scrutinize for insights into what a patient’s cancer might do. Analyzing these so-called circulating tumor cells (CTCs) isn’t part of routine care yet, in part because they’re so hard to pick out of the millions of normal cells in a blood sample. Still, scientists are making progress in this area. And in June, a research team reported that treatment decisions made on the basis of CTC testing had increased lifespans in men with an aggressive type of metastatic prostate cancer. Doctors usually treat metastatic prostate cancer with drugs that interfere with how a man’s body makes or uses testosterone, which is the male hormone (or androgen) that accelerates the tumor’s spread. If the standard hormone-blocking treatments aren’t effective, then doctors have two other options: they can either give chemotherapy drugs known as taxanes, or shift to other hormone blockers that act specifically on the cancer cell’s androgen receptor. Known as androgen receptor signaling (ARS) inhibitors, these alternative hormone blockers include an agent called enzalutamide and another called abiraterone. But neither of them will work if the androgen receptor has a genetic mutation called AR-V7 that also makes the tumors grow very aggressively. With mounting evidence showing that the mutation doesn’t affect a man’s response to taxanes, researchers began to wo...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Cancer Health Men's Health Prostate Health Source Type: blogs

Related Links:

RARITAN, NJ, May 13, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today results from the final analysis of the pivotal Phase 3 SPARTAN study demonstrating ERLEADA® (apalutamide) in combination with androgen deprivation therapy (ADT) significantly improved overall survival (OS), compared to ADT alone, in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who were at high risk of developing metastases.[i] Results will be presented at the American Society of Clinical Oncology (ASCO) Virtual Scientific Program (Abstract #5516) beginning May 29th. ERLEADA® i...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
AbstractStandard therapy for metastatic small cell carcinoma of the prostate (SCCP) remains undefined. We have effectively treated relapsed SCCP with amrubicin. A 72-year-old patient, diagnosed with T4N1M0 prostate cancer, started hormonal therapy in May 2012, elsewhere, and his prostate-specific antigen levels remained low. However, pulmonary and hepatic metastases occurred; high neuron-specific enolase levels suggested SCCP, which was confirmed by repeated biopsy at our institution. In October 2016, chemotherapy with irinotecan and cisplatin was initiated for metastases to the lung, liver, and left pelvic lymph nodes, an...
Source: International Cancer Conference Journal - Category: Cancer & Oncology Source Type: research
Treatments for prostate cancer are always evolving, and now research is pointing to new ways of treating a cancer that has just begun to spread, or metastasize, after initial surgery or radiation. Doctors usually give hormonal therapies in these cases to block testosterone, which is a hormone that makes the cancer grow faster. But newer evidence shows that treating the metastatic tumors directly with radiation can produce better results. In March, researchers published the latest study that supports this approach. Based at Johns Hopkins University School of Medicine in Baltimore, the team used a method for delivering power...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Living With Prostate Cancer Prostate Knowledge Treatments HPK Source Type: blogs
(Institute of Cancer Research) A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.Olaparib, a pill lacking the side effects of chemotherapy, can target an Achilles heel in prostate cancers with a weakness in their ability to repair damaged DNA.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
iot S, Pasquier D Abstract Prostate cancer is a sensitive adenocarcinoma, in more than 80% of cases, to chemical castration, due to its hormone dependence. Locally advanced and/or high-risk cancer is defined based on clinical stage, initial prostate specific antigen serum concentration value or high Gleason score. Hormone therapy associated with radiation therapy is the standard of management and improves local control, reduces the risk of distant metastasis and improves specific and overall survival. Duration of hormone therapy, dose level of radiation therapy alone or associated with brachytherapy are controvers...
Source: Cancer Radiotherapie - Category: Cancer & Oncology Authors: Tags: Cancer Radiother Source Type: research
Conditions:   Prostate Cancer;   Chemotherapy Effect;   Hormone Sensitive Prostate Cancer;   Locally Advanced Prostate Carcinoma Interventions:   Drug: Neoadjuvant chemotherapy combined with hormone therapy;   Drug: Neoadjuvant hormone therapy;   Procedure: Radical Prostatectomy (RP)+ extended lymph node dissection Sponsor:   RenJi Hospital Not yet recruiting
Source: - Category: Research Source Type: clinical trials
New England Journal of Medicine,Volume 381, Issue 26, Page 2564-2566, December 2019.
Source: New England Journal of Medicine - Category: Internal Medicine Authors: Source Type: research
Conclusions 177Lu-PSMA-617 radionuclide therapy is a safe and effective approach to the treatment of mCRPC patients.
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Original Articles Source Type: research
We present a case of de novo adenosquamous carcinoma of the prostate treated with a multimodal approach including surgery, androgen-deprivation therapy, chemotherapy, and radiation.
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research
More News: Blogging | Cancer | Cancer & Oncology | Chemotherapy | Genetics | Harvard | Hormonal Therapy | Hormones | Israel Health | Middle East Health | Prostate Cancer